+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain states that the Global Hereditary Angioedema Market Set To Grow To $2.8bn By 2022

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies
Hereditary Angioedema is a disorder characterized by reoccurring phenomena of severe swelling. Limbs, face airway and intestinal tract are the common areas of the body that swells up in this condition. This report evaluates the global market of hereditary angioedema in regions such as North America, Latin America, Europe, Asia-Pacific and the Middle East and Africa. Furthermore, this report provides detailed overview of various medical hereditary angioedema segments such as drug class, route of administration and distribution channel.
The lead analyst of the report commented “Hereditary angioedema (HAE) is a rare disease and the diagnosis of HAE is challenging in children. Lack of awareness, diagnostic testing limitations, and communication difficulties along with the differential diagnosis of the symptoms of this disorder contribute to this challenge. Delay in diagnosis leads to sub-optimal treatment of symptoms and reduced quality of life.”

Leading companies featured in the report include BioCryst Pharmaceuticals, Inc., CSL Limited, iBio, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV, Santarus, Inc., Shire PLC

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read